Why the study?
Does streptozotocin-induced moderate diabetes impair cardiac performance in spontaneously hypertensive and Wistar-Kyoto rats?
Does streptozotocin-induced moderate diabetes impair cardiac performance in spontaneously hypertensive and Wistar-Kyoto rats?
Imposition of moderate diabetes substantially impairs stress-loaded in vivo cardiac performance in spontaneously hypertensive rats, while producing only minor changes in normotensive Wistar-Kyoto rats.
Moderate diabetes impairs cardiac performance more in hypertensive than normotensive rats; hypothesis-generating for diabetes-hypertension interactions in humans.
To assess the effects of imposition of moderate diabetes on in vivo cardiac performance in gradually proceeding hypertension, spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY) were treated with streptozotocin (40 mg/kg) or vehicle at 8 weeks of age. Four and 20 weeks later, with the rats under ether anesthesia, peak cardiac output and stroke volume were measured during volume loading and peak left ventricular developed pressure and maximum rate of rise of pressure (dP/dtmax) were determined during aortic occlusion. Additionally, passive pressure-volume relations were obtained during saline infusion in potassium-arrested hearts, and the chamber stiffness constant was derived from one exponential function. There was a mortality of 16.1% in the diabetic SHR only. While basal and stressed cardiac performance was unchanged despite the already decreased mean arterial pressure and left ventricular weight at 4 weeks, the diabetic SHR revealed significant decreases in peak cardiac pumping indexes, peak left ventricular developed pressure, and dP/dtmax, with unchanged resting cardiac function, at 20 weeks. Changes seen in the diabetic WKY were reduced left ventricular weight at 4 weeks and reduced peak left ventricular dP/dtmax at 20 weeks. The chamber stiffness was unaltered with strain or diabetes. These data show that imposition of even moderate diabetes substantially influences the stress-loaded in vivo cardiac performance in the SHR, whereas it produces only minor changes in the WKY.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: